spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ERT Offers First Patient-Administered ECG Assessment for Continuation of Clinical Trials during COVID-19

ERT

Patients monitor cardiac safety at home with easy-to-use, FDA-cleared KardiaMobile 6L personal ECG




PHILADELPHIA – April 23, 2020 – ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a first-of-its-kind partnership with AliveCor, the leader in AI-based, personal ECG technology. The partnership enables ERT to capture digital cardiac safety data with KardiaMobile 6L, the only FDA-cleared personal ECG for patient-administered 6-lead data collection.

“By combining AliveCor’s advanced technology with our proven software and workflow platform, we are enabling our customers to continue developing new medical treatments during the COVID-19 pandemic, regardless of whether trial patients have physical access to investigative site personnel,” said Ellen Street, Executive Vice President of Cardiac Safety of ERT. “The device’s ease of use, combined with ERT’s centralized overread and data collection methodology make it an ideal solution for ensuring patient safety during ongoing clinical trials.”
KardiaMobile 6L is a hand-held, 6-lead personal ECG that records Lead II data without the attachment of electrodes. Data captured from the device will be integrated into ERT’s software and workflow platform and read by ERT cardiologists to ensure patient safety during the clinical development of new medical treatments. ERT provides high quality measurements for QTc, QRS, and other ECG intervals that enable efficacy and safety monitoring during clinical trials.

“ERT’s experience in analyzing millions of ECGs and their dedication to patient safety make them the gold standard in clinical trial cardiac safety assessment,” said Priya Abani, CEO of AliveCor. “We look forward to this partnership and to delivering the innovative solutions and valuable data that clinical trial sponsors require.”

Click here to learn more about ERT’s virtual clinical trial capabilities.
phone +1 800 961 5004
email eresearch@ert.com
web www.ert.com
email 1818 Market Street, Suite 1000, Philadelphia, PA 19103
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Pharma packaging giant announces significant expansion to warehouse facility

MARCH 2021 - Global pharmaceutical solutions provider, Origin, has opened a new warehouse facility in Scunthorpe, North Lincolnshire, expanding on its logistics site in Melton, East Riding of Yorkshire. The significantly larger site will create more stock holding for Origin’s UK and international pharmaceutical clients, as well as its own manufactured products that are supplied globally.
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement